

Longboard Pharmaceuticals, Inc. Policy on Expanded Access

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.

We are currently in the clinical testing stage of development. The completion of such controlled studies is required to generate the evidence regarding clinical safety and efficacy that is necessary to secure government approval and make new medicines available to a wider population of patients.

We understand that there may be interest in accessing our investigational medications prior to approval. At this time, our efforts are focused on the careful design and successful completion of clinical trials in collaboration with patients, families, advocacy groups, physicians, scientists and government agencies. We believe that this is the best way to generate information that may be critical to positively impact a much larger population in the future. Therefore, we encourage all eligible participants to consider enrolling in our ongoing or planned clinical trials, as we are not currently accepting requests for expanded access outside of the clinical trial setting. As development progresses, we will continue to evaluate potential appropriate opportunities to make our investigational medicines more broadly available and update this website should our policy change.

If you would like to register your interest in clinical trial participation, or to request information should an Expanded Access Program become available, you can visit the following link:
<https://www.longboardpharmaresearch.com/>

When completing the form, please be as specific as possible about the condition you or your loved one has so that we can best respond to you.

If you have any questions, please contact us at medinfo@longboardpharma.com and we will respond within five business days of receipt of your message.

Last updated: August 3, 2023